Seeking Alpha

An error in a Phase IIb trial for Cytokinetics' (CYTK) Tirasemtiv treatment for Lou Gehrig's...

An error in a Phase IIb trial for Cytokinetics' (CYTK) Tirasemtiv treatment for Lou Gehrig's disease caused 58 patients who initially received the drug to later receive a placebo. So far 50 patients have been enrolled in the trial. Cytokinetics now has to decide whether to raise the number of patients in the study, which could increase its costs and delay the results. Shares are about to resume trading after being halted.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|